--- title: "Kodiak Sciences | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285606535.md" datetime: "2026-05-07T20:02:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285606535.md) - [en](https://longbridge.com/en/news/285606535.md) - [zh-HK](https://longbridge.com/zh-HK/news/285606535.md) --- # Kodiak Sciences | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.94, beating the estimate of USD -1.0115. EBIT: As of FY2026 Q1, the actual value is USD -61.42 M. #### Net Loss Net loss for the first quarter of 2026 was - $58.2 million, or - $0.94 per share on a basic and diluted basis, compared to a net loss of - $57.5 million, or - $1.09 per share, for the first quarter of 2025 . This included non-cash stock-based compensation expense of $12.2 million in Q1 2026, down from $15.9 million in Q1 2025 . The net loss and comprehensive loss for Q1 2026 was - $58,158 thousand, compared to - $57,461 thousand for Q1 2025 . #### Operating Expenses Total operating expenses for the first quarter of 2026 were $59,777 thousand, an increase from $59,073 thousand in the first quarter of 2025 . #### Research and Development (R&D) Expenses R&D expenses were $48.5 million for the first quarter of 2026, an increase from $43.6 million for the first quarter of 2025 . This increase was primarily due to increased clinical activities related to the active PEAK/PINNACLE and DAYBREAK studies . Non-cash stock-based compensation expense included in R&D was $6.2 million in Q1 2026, down from $7.9 million in Q1 2025 . #### General and Administrative (G&A) Expenses G&A expenses were $11.2 million for the first quarter of 2026, a decrease from $15.4 million for the first quarter of 2025 . Non-cash stock-based compensation expense in G&A was $6.0 million in Q1 2026, compared to $8.0 million in Q1 2025 . Sublease income from a corporate office building also helped offset G&A expenses in Q1 2026 . #### Loss from Operations Loss from operations was - $59,777 thousand for Q1 2026, compared to - $59,073 thousand for Q1 2025 . #### Interest and Other Income/Expense Interest income was $1,641 thousand for Q1 2026, slightly up from $1,602 thousand for Q1 2025 . Other income (expense), net, was - $22 thousand for Q1 2026, compared to $10 thousand for Q1 2025 . #### Cash Position Kodiak Sciences Inc. ended the first quarter of 2026 with $169.5 million in cash and cash equivalents, a decrease from $209,862 thousand at December 31, 2025 . The company believes its current cash and cash equivalents will support operations into 2027 . #### Working Capital Working capital was $125,685 thousand at March 31, 2026, down from $169,283 thousand at December 31, 2025 . #### Total Assets Total assets were $306,006 thousand at March 31, 2026, compared to $351,533 thousand at December 31, 2025 . #### Accumulated Deficit Accumulated deficit was - $1,616,863 thousand at March 31, 2026, an increase from - $1,558,705 thousand at December 31, 2025 . #### Total Stockholders’ Equity Total stockholders’ equity was $112,101 thousand at March 31, 2026, down from $157,383 thousand at December 31, 2025 . #### Operational Highlights and Outlook Kodiak Sciences Inc. announced positive topline results for the GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy . The company anticipates topline data from the DAYBREAK Phase 3 study for Zenkuda and KSI-501 in wet AMD in September 2026, and for the PEAK Phase 3 study of KSI-101 in MESI in December 2026 . Enrollment is progressing for the PEAK and PINNACLE studies of KSI-101, with PINNACLE topline results expected in Q2 2027 . ### Related Stocks - [KOD.US](https://longbridge.com/en/quote/KOD.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)